Table 2 Group I and II: agreement (%), sensitivity (%), and specificity (%) of FOI, CE, GSUS, and PDUS vs CE, GSUS, and PDUS as standards of reference
CE | GSUS | PDUS | |||||||
|---|---|---|---|---|---|---|---|---|---|
Agreement | Sensitivity | Specificity | Agreement | Sensitivity | Specificity | Agreement | Sensitivity | Specificity | |
Group I: JIA with clinically active arthritis in the hand region | |||||||||
FOI any phase | 66.6 | 75.2 | 63.9 | 65.7 | 67.3 | 65.0 | 60.6 | 72.0 | 58.8 |
PVM | 78.2 | 41.7 | 89.5 | 67.9 | 28.1 | 86.9 | 78.2 | 35.6 | 84.8 |
P1 | 72.3 | 56.3 | 77.2 | 70.5 | 51.8 | 79.7 | 72.1 | 59.8 | 74.0 |
P2 | 71.8 | 62.6 | 74.7 | 66.7 | 51.2 | 74.0 | 67.9 | 57.6 | 69.5 |
P3 | 75.3 | 19.4 | 93.1 | 69.5 | 18.6 | 94.3 | 81.9 | 20.3 | 91.7 |
CE | – | – | – | 71.1 | 42.0 | 85.1 | 78.2 | 56.8 | 81.5 |
GSUS | 71.1 | 57.3 | 75.5 | – | – | – | 80.3 | 96.6 | 77.8 |
PDUS | 78.2 | 32.5 | 92.3 | 80.3 | 40.6 | 99.3 | – | – | – |
Group II: non-inflammatory joint diseases | |||||||||
FOI any phase | 75.0 | 0.0 | 75.0 | 72.1 | 39.4 | 77.3 | 75.5 | 61.5 | 75.7 |
PVM | 93.3 | 0.0 | 93.3 | 84.6 | 18.1 | 95.1 | 92.3 | 23.1 | 93.6 |
P1 | 88.0 | 0.0 | 88.0 | 80.1 | 21.3 | 89.4 | 86.6 | 15.4 | 88.0 |
P2 | 83.2 | 0.0 | 83.2 | 77.1 | 27.7 | 84.9 | 83.3 | 53.8 | 83.9 |
P3 | 98.2 | 0.0 | 98.2 | 86.0 | 4.5 | 98.6 | 97.1 | 23.1 | 98.6 |
CE | – | – | – | 86.4 | 0.0 | 100.0 | 98.1 | 0.0 | 100.0 |
GSUS | 86.4 | 0.0 | 86.4 | – | – | – | 87.7 | 84.6 | 87.7 |
PDUS | 98.1 | 0.0 | 98.1 | 87.7 | 11.7 | 99.7 | – | – | – |